Attending the 2026 Bladder & Kidney Cancer Academy Meeting in Denver, CO, September 24-26? Visit our booth to learn how #DecipherTesting by @Veracyte, Inc. can help support treatment planning in #ProstateCancer and #BladderCancer. #PrecisionMedicine #DecipherUrologicCancers

We’re at Frontiers in Oncologic Prostate Care and Ablative Local Therapy FOCAL+ 2026, September 24-26 in San Diego, CA! Visit our booth to learn how #DecipherTesting by @Veracyte can support more informed treatment decisions for patients with #ProstateCancer. #PrecisionMedicine

Attending the 2026 Bladder & Kidney Cancer Academy Meeting in Denver, CO, September 24-26? Visit our booth to learn how #DecipherTesting by @Veracyte can help support treatment planning in #ProstateCancer and #BladderCancer. #PrecisionMedicine #DecipherUrologicCancers

We're at the 40th Reed M. Nesbit Urologic Society & Visiting Professor Meeting in Ann Arbor, MI! Visit our booth on September 18 to learn how #DecipherTesting by @Veracyte, Inc. can help support more informed, personalized treatment decisions in #ProstateCancer & #BladderCancer

We're attending the Unio Specialty Care Summit in Long Beach, CA September 18-19! Visit our booth to connect with our team and learn how #DecipherTesting by @Veracyte, Inc. can help inform treatment planning in #ProstateCancer & #BladderCancer.  #DecipherUrologicCancers

#TeamVeracyte is at the Erlanger Scenic City Urology Symposium 2026, September 18-19 in Rising Fawn, GA! Stop by our booth to learn how #DecipherTesting can help provide actionable insights for treatment planning for those with #ProstateCancer & #BladderCancer. @Veracyte

Prostate Cancer Awareness Month (PCAM) is a time to focus on the people behind every diagnosis – and the questions, decisions, and care teams that shape each patient’s path forward. Behind every study, every test result, and every treatment decision is a person looking for answers. With that in mind, PCAM also serves as an opportunity to reflect on how ongoing research into tools such as genomic testing are helping inform more personalized conversations about prostate cancer care. Veracyte is incredibly proud that the Decipher® Prostate Genomic Classifier continues to help providers and patients get answers. Over the years, a wide-ranging collection of publications supports the use of the Decipher Prostate test in prostate cancer care decision-making, helping clinicians and their patients navigate treatment choices with clarity through genomic insights. Veracyte continues to build on that foundation. This work takes time, investment, and follow-through, and reflects Veracyte’s broader commitment to helping advance prostate cancer care. As we honor Prostate Cancer Awareness Month, our team wrote a piece to discuss the latest clinical research featuring the Decipher Prostate test and how it helps patients. | Key Topics Covered | 🔹 How the #DecipherProstate test works 🔹 Results from the ENZAMET Trial 🔹 The latest research on predicting cancer progression 🔹 A preview of new studies being presented at ASTRO 2026 🔗 For more, read the full piece here -  veracyte.com/company/blog/fr… #ProstateCancer #ProstateCancerAwareness #PrecisionMedicine Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/legal/cautionar…

Join #TeamVeracyte September 17-19 at the 78th Annual Meeting of the Northeastern Section of the AUA in Rochester, NY! Stop by, to learn how Decipher® Prostate & Decipher® Bladder testing provide genomic insights to support care decisions in prostate and bladder cancer. @Veracyte

We're here at the Georgia Urological Association (GUA) 2026 Annual Fall Meeting in Sea Island, GA! Learn how #DecipherTesting by @Veracyte can help support clinical decision-making across #ProstateCancer & #BladderCancer care. Stop by and meet the team; we'd love to connect!

Attending the 105th Annual Meeting of the South Central Section of the AUA? Let's connect! Stop by the @Veracyte, Inc. booth Sept 10-12 in Tucson, AZ, to meet our team & learn how we can help support more personalized care for patients with #ProstateCancer & #BladderCancer

We’re excited to be exhibiting at the Mid-Atlantic AUA 84th Annual Meeting, September 10-11, 2026. Visit our booth to learn how #DecipherTesting by @Veracyte, Inc. can help provide additional clarity for treatment planning. #DecipherUrologicCancers #PrecisionMedicine

We're heading to the Georgia Urological Association 2026 Annual Fall Meeting (GUA)! Visit our booth Sept. 10-13 in Sea Island, GA, to learn how Decipher® Prostate & Decipher® Bladder testing can help support treatment planning in #ProstateCancer & #BladderCancer care. @Veracyte

We’re here at the 84th Annual Mid Atlantic Section of the AUA meeting September 9-11, 2026! Visit the #TeamVeracyte booth to learn how Decipher® Prostate & Decipher® Bladder testing help support a personalized approach to care for those with prostate & bladder cancer. @Veracyte

We’re at the 105th Annual Meeting of the South Central Section of the AUA! Visit us September 9-12 in Tucson, AZ, to learn how #DecipherTesting by @Veracyte, Inc. can help provide additional information to support treatment planning in #ProstateCancer & #BladderCancer patients.

We're excited to be at the 2026 PAMA Convention in Palm Coast, FL, September 4-7. Visit the our booth to connect with our team & learn how Decipher® Prostate and Decipher® Bladder testing can help support treatment planning in #ProstateCancer & #BladderCancer. @Veracyte

Join us in Palm Coast, FL, September 4-7 for the 2026 PAMA Convention. Stop by our booth to learn how #DecipherTesting by Veracyte, Inc. can help inform help support more personalized treatment planning in #ProstateCancer and #BladderCancer. #DecipherUrologicCancers

We are at the Louisiana Urological Society (LUS) 2026 Annual Meeting in Bossier City, LA. Visit our booth today to learn how #DecipherProstate testing by @Veracyte, Inc. is helping transform #ProstateCancer care! #UrologicCancer #PrecisionMedicine

A new publication shares results from primary and biomarker analyses of the phase 2 SURE-01 trial. The trial evaluated sacituzumab govitecan prior to radical cystectomy in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based neoadjuvant chemotherapy. Molecular profiling using the Decipher® Bladder Genomic Subtyping Classifier indentified higher pathologic complete response rates to treatment with sacituzumab govitecan in patients with non-luminal tumors (46%) than among those with luminal tumors (14%). This finding highlights the potential value of molecular subtyping for indentifying differences in treatment responses and advancing a more personalized approach to bladder cancer management. ➡️ Read the complete findings here: ascopubs.org/doi/10.1200/JCO… | Resources | 🔗 Learn more about Decipher Bladder: veracyte.com/tests/decipher-… 📄 Explore all Decipher Bladder Scientific Publications: veracyte.com/resources/scien… #MIBC #MolecularSubtyping #ClinicalResearch #DecipherUrologicCancers Note: This post contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/cautionary-note…

We're attending the Louisiana Urological Society (LUS) 2026 Annual Meeting in Bossier City, LA, August 21-22! Visit our booth to connect with our team and learn how #DecipherTesting by @Veracyte helps bring added clarity and confidence in #ProstateCancer treatment planning.

We’re here at the 2026 Joint Annual Meeting of the Oregon Urology Society and Washington State Urology Society in Stevenson, WA! Visit our booth today or tomorrow to learn how #DecipherTesting by @Veracyte, Inc. is helping personalize #ProstateCancer & #BladerCancer care!